Incepta Vaccine Ltd is the first human vaccine manufacturing company in Bangladesh that acquires the knowledge and technology to manufacture vaccines for human use. The manufacturing unit is situated at Zirabo, Savar which is conveniently located at the outskirt of Dhaka city. We are completely devoted to protect the vast population of Bangladesh as well as developing world from various infectious illnesses and thereby reducing the mortality rate from fatal diseases.
Incepta Vaccine Ltd was launched in June 2011 with the prime objective of providing vaccines at an affordable cost. We have a vision to continue developing novel vaccines against diseases of the developing world.
Currently, our portfolio includes vaccines against bacterial and viral diseases in the market. We have also some immunoglobulin preparations to provide immediate protection against fatal diseases which are vulnerable on contact where only vaccine cannot give total protection. We are committed to manufacture preventive medicines against all possible life-threatening infectious diseases.
Incepta Vaccine Ltd has a state-of-the-art facility fully compliant with WHO GMP guideline. The large vaccine facility has the capacity to manufacture 180 million single dose vials and ampoules per year. This huge capacity can meet the requirements of vaccines locally and globally. A large pool of scientists are engaged in different areas of specialties like research and development, quality control, quality assurance, production and other related areas.
An advanced fully GMP compliant Research & Development facility has been developed, which can independently handle several projects simultaneously involving organisms. For this purpose, a group of young, energetic and talented researchers across the globe is employed who are working relentlessly on innovative ways of developing vaccines as a commitment to serve the humanity.
A bulk antigen facility compliant with WHO GMP requirements has been developed providing the best environmental conditions for performing the operations. The facility can manufacture both Bacterial and Viral bulk antigen. Bulk antigen facility is equipped with modern production fermenters with capacity of 1500 L, 750 L and 500 L.
Immunogenicity and safety is the prime required measures of any vaccine. A world class large lab animal house has been developed where vaccines are directly tested in animal to measure the potency, safety and immunogenicity.
Incepta Vaccine Ltd ensures the quality of vaccine having a validated well-designed and equipped cold chain system from factory to final delivery point. Many classified and unclassified cold rooms (from temperature -20 oC to +10 oC) are in place to store all critical material at required temperature to maintain their efficacy. For distribution of vaccines, we have cold vans, cold chain box, and an airliner. Our vaccines are stored in big cold rooms in depots spread across the nation.